Our results also showed the correlation of SEMA4D and VEGF positive expressions were closely in EOC tissues, which hinted targeting SEMA4D might serve as a parallel option for traditional antiangiogenic therapy with single regimen in ovarian cancer. This evidence concerns the gene VEGFA and ovarian carcinoma.